Application of Modified Mupit for the Recurrent Vulva Cancer in Brachytherapy

  • Kim, Jong-Sik (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jung, Chun-Young (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Oh, Dong-Gyoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Song, Ki-Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Young-Hwan (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 김종식 (성균관대학교 의과대학, 삼성서울병원 방사선종양학과) ;
  • 정천영 (성균관대학교 의과대학, 삼성서울병원 방사선종양학과) ;
  • 오동균 (성균관대학교 의과대학, 삼성서울병원 방사선종양학과) ;
  • 송기원 (성균관대학교 의과대학, 삼성서울병원 방사선종양학과) ;
  • 박영환 (성균관대학교 의과대학, 삼성서울병원 방사선종양학과)
  • Published : 2005.06.01

Abstract

Introduction: To evaluate whether modified MUPIT applicator can effectively eradicate recurrent tumor in uterine cervix cancer and reduce rectal complication after complete radiation treatment. Methods and Materials: Modified MUPIT applicator basically consists of an acrylic cylinder with flexible brain applicator , an acrylic template with a predrilled array of holes that serve as guides for interstitial needles and interstitial needles. CT scan was performed to determine tumor volume and the position of interstitial needles. Modified MUPIT applicator was applied to patient in operation room and the accuracy for position of interstitial needles in tumor volume was confirmed by CTscan. Brachytherapy was delivered using modified MUPIT applicator and RALS (192-Ir HDR) after calculated computer planning by orthogonal film. The daily dose was 600cGy and the total dose was delivered 3000cGy in tumor volume by BID. Rectal dose was measured by TLD at 5 points so that evaluated the risk of rectal complication. Result: The application of modified MUPIT applicator improved dramatically dose distributions in tumor volume and follow-up of 3 month for this patient was clinically partial response without normal tissue complication, Rectal dose was measured 34.1cGy, 57.1cGy, 103.8cGy, 162.7cGy, 165.7cGy at each points, especially the rectal dose including previous EBRT and ICR was 34.1cGy, 57.1cGy Conclusion: Patients with locally recurrent tumor in uterine cervix cancer treated with modified MIUPIT applicator can expect reasonable rates of local control. The advantages of the system are the fixed geometry Provided by the template and cylinders, and improved dose distributions in irregular tumor volume without rectal complication

재발한 vulva tumor의 근접 치료에 있어서 정상조직의 장애와 tumor volume내의 dose uniformity는 치료성적에 매우 중요한 요인이다. 이를 개선하기 위하여 modified MUPIT applicator를 제작하여 modified MUPIT applicator의 적용에 대한 유용성을 평가하고자 한다. modified MUPIT applicator는 template, cylinder, interstitial needle로 구성되었으며, tumor volume을 정하기 위하여 CT를 시행하였다. CT image를 이용하여 interstitial needle의 삽입 위치를 확인하고 수술실에서 template 를 치료 부위에 고정을 시키고 cylinder를 vaginal cavity에 삽입한 후 interstitial needle을 tumor volume 내에 삽입 하였다. tumor volume내에서 interstitial needle의 정확한 위치를 확인하기 위하여 CT를 시행하였으며 orthogonal film을 이용하여 computer planning을 실시하였다. daily tumor dose는 600 cGy, BID로 3000 cGy를 조사하였으며 치료 시 rectal dose를 평가하기 위하여 TLD를 이용하여 anal verge를 기준으로 5개 지점에서 rectal dose를 측정하였다. rectal dose는 34.1 cGy, 57.1 cGy, 103.8 cGy, 162.7 cGy, 165.7 cGy로 측정되었으며 EBRT(whole pelvis RT), ICR과 overlap되는 지점은 34.1 cGy, 57.1 cGy로 매우 우수하게 평가되었다. 결론적으로 자체 제작한 modified MUPIT applicator 사용하여 interstitial brachytherapy를 시행함으로써 EBRT로 cover하기 어려운 환자의 tumor volume내에서 irregularity를 효율적으로 극복할 수 있었고 우수한 rectal dose 분포를 통하여 rectal complication의 발생 확률을 현저히 감소시킬 수 있었다.

Keywords